EGFR and non-small cell lung carcinoma: Despite the dramatic initial responses to single-agent EGFR tyrosine kinase inhibitors (TKIs) in EGFR mutation-positive NSCLC patients, 70% of them relapse within one year of initiation of therapy[7, 8, 27].